Canada markets close in 3 hours 34 minutes

Bausch Health Companies Inc. (BHC)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
6.88-0.51 (-6.97%)
As of 12:26PM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • P
    Pam
    What am I missing? 50% of BLCO is $8.12 ($16.24/2) + any stand alone value of BHC is greater than $7.03. Doesn’t the market think BHC shareholders will get BLCO?
  • J
    Jeffrey
    BHC has the WORST percentage DECLINE of all Pharma stocks today (10/7).
    NOTHING NEW about that.
  • C
    Constantine
    If market continues to improve can they still sell the second 10% to raise capital? Or is that off the table?
  • J
    Jeffrey
    ALL BHC Shorters would like to thank JOE PAPA for taking BHC DOWN from $47 to $4.
    At the same time, JOE PAPA put OVER $340,000,000 into Joe Papa's own pocket, with the Millions & Millions of FREE BHC shares that Joe Papa gave to himself, which Joe Papa Sold in the mid-$30s.
  • M
    Marc
    Heres one for Duke:

    S&P Upgrades Bausch Health, Affirms Rating on Bausch + Lomb
    BY MT Newswires
    — 10:52 AM ET 10/05/2022
    10:52 AM EDT, 10/05/2022 (MT Newswires) -- S&P Global Ratings on Tuesday upgraded the issuer credit rating on Bausch Health Cos (BHC). (BHC.TO) to CCC+ from SD.

    The outlook is stable. The rating agency assigned its B- issue-level rating to the new first-lien notes and CCC issue-level rating to the new second-lien notes.

    S&P downgraded the issue-level ratings on the company's existing secured debt to B- from B to reflect the increased proportion of secured debt in the capital structure. S&P lifted its issue-level ratings on the existing unsecured debt to CCC from D.

    Also, S&P on Tuesday its issuer credit rating on Bausch + Lomb Corp. (BLCO) at CCC+. The stand-alone credit profile on the company remains b+.

    The agency affirmed its rating on Bausch + Lomb's (BLCO) senior secured credit facility at CCC+. The outlook is positive.

    "We cap our rating on B+L to that of BHC because we do not consider B+L an insulated subsidiary and believe the relatively weaker parent could divert assets from B+L or burden it with liabilities during financial stress," the agency said.

    On last look on Wednesday, Bausch Health's (BHC) shares were up 0.8% while Bausch + Lomb's (BLCO) shares were down 1.1%.

    Price: 10.33, Change: +0.14, Percent Change: +1.37

    MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
  • J
    Jeffrey
    Thanks to your JOE PAPA, BHC has been stuck in the mid-SINGLE DIGITS or LOWER for the past 6 months.
    Thank you, JOE PAPA, for COMPLETELY DESTROYING BHC, by taking BHC DOWN from $47 (when JOE PAPA took over BHC) TO $4.
  • M
    Marc
    VI45

    The final results of the debt swap have been released by BHC...let the impact / spin guessing game begin!
  • M
    Marc
    Jeffrey

    In all seriousness...what is the source of your beef with BHC. Did you used to work for them or have you been following them for a long time. Not trying to antagonize here...just trying to understand where you are coming from.
  • M
    Marc
    VI45

    Whats your read on the second part about Xifaxan

    RBC Capital on Bausch Health -- Notes Net Debt Reduced by ~$2.5 Billion; BLCO Can Now be Unrestricted
    BY MT Newswires
    — 12:13 PM ET 09/29/2022
    12:13 PM EDT, 09/29/2022 (MT Newswires) -- Based on the final results from the debt exchange offer, Bausch Health (BHC) will be able to reduce net debt by ~$2.5 billion at RemainCo. RBC Capital estimates the leverage at RemainCo will drop from ~8x (as of Q2/22) to ~7x, below the 7.6x needed to un-restrict Bausch + Lomb (BLCO) as per the BHC debt covenants, however management has guided to (and may further revise) its guidance of ~6.5x-6.7x before the distribution of BLCO to BHC shareholders can be made.

    RBC believes the 50.1% of BLCO distribution to BHC shareholders could occur by H1/23.

    Xifaxan patent litigation:

    RBC is closely monitoring the developments in the Xifaxan patent litigation. Based on the recent court documents, Norwich has amended its abbreviated new drug application (ANDA) and is targeting a "skinny" label approval only for IBS-D. Norwich is also seeking a modification to the Aug 10 district court ruling which prevents FDA approval for Norwich's original ANDA before Oct 2, 2029. "Given that Norwich has modified its ANDA, we expect the May 12 stipulation agreement to not apply and consequently a number of the 19 patents that were not addressed during the March bench trial may be litigated."

    RBC Capital has a Sector Perform and US$8 target on the stock.

    Price: 9.88, Change: -0.29, Percent Change: -2.85
  • P
    Pepe
    Imagine buying this at $22 like Cramer did
  • J
    Jeffrey
    Philippe is Gino's 3rd ID, which he started on 10/3/2022. Philippe's other 2 IDs are Gino & Guido.
    Philippe posted on another stock message board this -->>>>> "I'm Philippe/Gino/Guido. I Philippe/Gino/Guido am SHORTING the HELLO out of BHC BIG EVERY DAY for the rest of 2022."
  • H
    Hugh
    Are BHC shares holders ever going to receive BLCO shares for the company split?
    If so WHEN?
  • J
    Jeffrey
    How LOW can BHC go?
    Don't worry, BHC can go MUCH LOWER.
  • M
    Marc
    Pam / Constantine

    I'm with you...I dont get it. I would think north of $10 at least, but 12-15 makes a lot of sense.
  • D
    Duke
    BHC owns & controls 88.7% BLCO. Curious how BLCO "news" doesn't appear under BHC media space.
    "Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of enhanced Ocuvite Adult 50+ eye vitamin with 30 micrograms of vitamin D, an antioxidant proven to help support healthy cell function, which is key to protecting eye health.* The enhanced Ocuvite vitamin will replace the currently offered Ocuvite Adult 50+."
  • J
    Jeffrey
    Philippe/Gino/Guido posted yesterday that BHC will be BANKRUPT in 2023.
  • J
    Jeffrey
    Philippe/Gino/Guido (SAME person with 3 IDs) NEVER posts ANYTHING about BHC. Philippe/Gino/Guido ONLY posts about Jeffrey & Gladiator 24/7/365. Philippe/Gino/Guido is OBSESSED with Jeffrey & Gladiator 24/7/365. Philippe/Gino/Guido thinks about Jeffrey & Gladiator 24/7/365. Philippe/Gino/Guido dreams about Jeffrey & Gladiator 24/7/365. Philippe/Gino/Guido can't stop thinking about Jeffrey & Gladiator 24/7/365.
  • M
    Marc
    Jeffrey

    As I mentioned, to give credit where it is due YOU were the only one calling for the complete collapse of BHC way, way back when. I put you on ignore 6 months ago because your delivery was such a turn off, but we all have to face facts and YOU CALLED IT. Hopefully the next chapter turns out much differently.
  • J
    Jeffrey
    Philippe/Gino/Guido (SAME person with 3 IDs) NEVER posts ANYTHING about BHC. Philippe/Gino/Guido ONLY posts about Jeffrey & Gladiator 24/7/365. Philippe/Gino/Guido is OBSESSED with Jeffrey & Gladiator 24/7/365. Philippe/Gino/Guido thinks about Jeffrey & Gladiator 24/7/365. Philippe/Gino/Guido dreams about Jeffrey & Gladiator 24/7/365. Philippe/Gino/Guido can't stop thinking about Jeffrey & Gladiator 24/7/365.
  • P
    Philippe
    Who is that clown Jeffrey who constantly posts things here that have no added value?
    He can't even name the president of the USA, so apparently he doesn't have much common sense.
    Incomprehensible that Yahoo tolerates such people on their forum!